TMCnet News
CureApp Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health StartupsNEW YORK, Aug. 24, 2020 /PRNewswire/ -- CB Insights today named CureApp to its second annual Digital Health 150 ranking, which showcases the 150 most promising private digital health companies in the world. The 2020 Digital Health 150 cohort highlights startups that are reimagining the lines of the traditional healthcare experience across 12 categories, from Virtual Care Delivery and Clinical Trials, to Drug Discovery and Specialty Care. Countries represented this year include Canada, China, Israel, France, the United Kingdom, and the United States, among others. "This year's Digital Health 150 is our most global ever, covering the best private healthcare companies from 17 countries. Beyond geographic diversity, these companies are innovating across the entire healthcare value chain, spanning technologies that benefit pharma & biotech companies, to payers, hospitals, insurers, and more," said CB Insights CEO Anand Sanwal. "Last year's Digital Health 150 winners saw numerous exits and went on to raise nearly $5 billion in investor financing after being recognized. We look forward to seeing the success of this year's class of the best in digital health." Kohta Satake, M.D. President and CEO, CureApp,Inc It is an incredible honor to have CureApp selected as one of the "Digital Health 150 Companies" again this year. Software and app-based therapeutics have the potential to produce a therapeutic effect that matches and exceeds current medical treatments that rely on medicinal drugs and medical devices. Apps can be used to improve lifestyle choices and prompt behavioral changes to treat the root cause of ailments while minimizing drug prescriptions, helping cut down on medical costs. Therapeutic apps continue to attract attention the world over, with many companies pursuing research and development in this area, and CureApp currently stands as the only company performing clinical trials in multiple disease areas. Looking ahead, we will continue to work as a leading company in the therapeutic app industry, accelerating research and development with a view to spreading therapeutic apps for various ailments in Japan and abroad, while continually striving to provide patients the world over with new treatment options. Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from hundreds of applications based on several factors including patent activity, investor quality, news sentiment analysis, proprietary Mosaic scores, market potential, partnerships, competitive landscape, team strength, and tech novelty. The Mosaic Score, based on CB Insights' algorithm, measures the overall health and growth potential of private companies to help predict a company's momentum. CureApp's products embrace the power of technology and the deep medical knowledge of healthcare professionals to effectively provide patient-tailored personalizedguidance. Encouraging patients to improve their lifestyle by raising their awareness and changing their behavior ultimately leads to the improvement of their disease conditions. CureApp was the first company to launch DTx clinical studies in Japan, pioneering the field. In 2019, they completed a large-scale phase III randomized control trial for their first product for nicotine addiction, which is currently under review for the first-ever DTx regulatory approval in Japan. Development and clinical trials on therapeutic applications for hypertension and NASH (non-alcoholic steatohepatitis) are also underway. They founded their U.S. subsidiary last year to leverage their advancement in the field in Japan and begin to rollout a global operation. Quick facts on the 2020 Digital Health 150:
The Digital Health 150 Companies (in alphabetical order): 98Point6 Abacus Insights AbCellera Biologics Aetion Akili Interactive Labs Alan Aledade Alpha Health Arterys Atomwise Avail Medsystems Axial Healthcare Babyscripts Bend Financial Bigfoot Biomedical Bind Benefits Biofourmis Biointellisense Bright Health Bright.MD BrightInsight Brightside Benefit Cala Health Capsule Caption Health Carbon Health Carrot Fertility Cedar Celsius Therapeutics ChromaCode Cityblock Health CMR Surgical Concerto HealthAI Cricket Health Cue Health CureApp Current Health Dental Monitoring Devoted Health DispatchHealth DNAnexus Doctolib Doctor On Demand Dreem Eko Element Science Evidation Health Firefly Health Folx Health Freenome Galileo Health Genome Medical GRAIL GYANT HaloDoc Happify Health Healthy.io Healx Heartbeat Hims & Hers Hinge Health icometrix iLoF Incredible Health Infervision Innovaccer Insilico Medicine Insitro Iora Health K Health Kaia Health Karius Kindbody Komodo Health League LeanTaaS LetsGetChecked Livi Lunit Lyra Health Mahmee Mammoth Biosciences Maven Clinic Medable Medbanks Network Technology Medically Home Group MediTrust Health Meru Health Mindbloom Mindstrong Modern Fertility Mojo Vision mPharma nference Notable Nuvo Group Olive Omada Health Oncology Analytics Onera Health Oscar Health Oura OWKIN PAIGE.AI Parsley Health PathAI Pear Therapeutics Perspectum PharmEasy ProteinQure Protenus Quartet Health Qure.ai RDMD Ready Responders Recursion Pharmaceuticals Redox Ro Saama Technologies Science 37 Sema4 Somatus SonarMD SOPHiA Genetics Subtle Medical Taimei Technology Tempus Tencent Trusted Doctors Thrive Earlier Detection TriNetX Truepill Twistle TytoCare Unite Us Unlearn Valencell Verana Health Vesta Healthcare Vicarious Surgical VillageMD Vim Vineti Virta Health Viz.ai We Doctor Wellth Winterlight Labs Xealth XtalPi Zebra Medical Vision About CB Insights At CB Insights, we believe the most complex strategic business questions are best answered with facts. We are a machine intelligence company that synthesizes, analyzes and visualizes millions of documents to give our clients fast, fact-based insights. Serving the majority of the Fortune 100, we give companies the power to make better decisions, take control of their own future, and capitalize on change. About CureApp CureApp, Inc. is a MedTech start-up company that performs research and development and produces software as a medical device for disease treatments based on advanced software technology and medical evidence. CureApp pursues the research and development of "Digital Therapeutics", a disease treatment app, to establish a new form of medical service in Japan with a concept of "an app that cures diseases"."Digital Therapeutics" draws on a daily therapeutic process tailored to each patient to provide new therapeutic effects through analysis and guidance based on medical knowledge and evidence. Encouraging patients to improve their habits through raising their awareness and changing their behavior may also contribute to disease improvement. At present, the development status of "Digital Therapeutics" is as follows.
URL: https://cureapp.co.jp/en/index.html View original content to download multimedia:http://www.prnewswire.com/news-releases/cureapp-named-to-the-2020-cb-insights-digital-health-150----list-of-most-innovative-digital-health-startups-301116994.html SOURCE CUREAPP,INC. |